Branding/Logomark minus Citation Combined Shape Icon/Bookmark-empty Icon/Copy Icon/Collection Icon/Close Copy 7 no author result Created with Sketch. Icon/Back Created with Sketch. Match!
Emre Tekgündüz
University of Health Sciences Antigua
86Publications
8H-index
172Citations
Publications 86
Newest
Published on Feb 14, 2019in Scientific Reports 4.01
Sinem Namdaroglu2
Estimated H-index: 2
(UHSA: University of Health Sciences Antigua),
Ali Hakan Kaya3
Estimated H-index: 3
(UHSA: University of Health Sciences Antigua)
+ 6 AuthorsFevzi Altuntas14
Estimated H-index: 14
(UHSA: University of Health Sciences Antigua)
Post-transplant cyclophosphamide has become a promising medical option after allogeneic HSCT. In this study we aimed to evaluate the efficacy of cyclophosphamide and cyclosporine combination in acute and chronic graft-versus-host disease (GvHD) prophylaxis in acute myeloid leukemia (AML) cases scheduled for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Retrospective analysis of data from 40 cases who underwent allogeneic HSCT under GvHD prophylaxis with cyclophosphamide and cyc...
Published on Apr 2, 2019in Journal of Oncology Pharmacy Practice 1.83
Merih Kızıl Çakar3
Estimated H-index: 3
(UHSA: University of Health Sciences Antigua),
Merih Kızıl Çakar (UHSA: University of Health Sciences Antigua)+ 12 AuthorsJale Yıldız1
Estimated H-index: 1
(UHSA: University of Health Sciences Antigua)
IntroductionThe aim of this study was to investigate the influence of high-dose cytosine arabinoside (HDAC)-containing treatments followed by autologous hematopoietic stem cell transplantation on the survival of patients with mantle cell lymphoma.Material and methodsThe data of 27 MCL patients who were followed-up between January 2009 and December 2015 were analyzed retrospectively.ResultsThe median age of the patients was 63 (range, 45–82) with 22 (81.4%) males and 5 (18.6%) females. Eight of 2...
Published on Feb 1, 2018in Transfusion and Apheresis Science 1.41
Fatih Demirkan11
Estimated H-index: 11
,
Emre Tekgündüz8
Estimated H-index: 8
Published on Feb 1, 2018in Transfusion and Apheresis Science 1.41
Emre Tekgündüz8
Estimated H-index: 8
,
Mehmet Yilmaz24
Estimated H-index: 24
(University of Gaziantep)
+ 25 AuthorsIrfan Kuku12
Estimated H-index: 12
(İnönü University)
Abstract Thrombotic microangiopathies (TMAs) are rare, but life-threatening disorders characterized by microangiopathic hemolytic anemia and thrombocytopenia (MAHAT) associated with multiorgan dysfunction as a result of microvascular thrombosis and tissue ischemia. The differentiation of the etiology is of utmost importance as the pathophysiological basis will dictate the choice of appropriate treatment. We retrospectively evaluated 154 (99 females and 55 males) patients who received therapeutic...
Published on Feb 1, 2018in Transfusion and Apheresis Science 1.41
Mehmet Hilmi Dogu3
Estimated H-index: 3
,
Hikmetullah Batgi2
Estimated H-index: 2
+ 7 AuthorsFevzi Altuntaş4
Estimated H-index: 4
Abstract In this study, we aimed to investigate whether the procedure and product kinetics differ according to age groups in advanced-age MM patients who underwent autologous HSCT. 59 patients who underwent autologous HSCT were retrospectively analyzed. Then, the patients were divided into two groups as 60–65 years and ≥65 years. It was significantly lower in ≥65 years group (p = 0.008) and proportionally, the procedure duration was also significantly shortened in this group (p = 0.013). Total n...
Published on Dec 1, 2017in Transfusion and Apheresis Science 1.41
Ömür Kayıkçı2
Estimated H-index: 2
,
Emre Tekgündüz8
Estimated H-index: 8
+ 7 AuthorsFevzi Altuntaş4
Estimated H-index: 4
Abstract Biosimilar filgrastim (Leucostim ® ) was shown to be similar in terms of efficacy and safety in hematopoietic progenitor cell mobilization (HPCM) compared to originator filgrastim (Neupogen ® ) and lenograstim (Granocyte ® ) in healthy donors and chemomobilization settings. Here we report our retrospective experience with Leucostim ® (n: 43) compared to Neupogen ® (n: 71) and Granocyte ® (n: 32) in steady-state mobilization of patients presenting with Hodgkin lymphoma, non-Hodgkin lymph...
Published on Dec 1, 2017in Transfusion and Apheresis Science 1.41
Emre Tekgündüz8
Estimated H-index: 8
,
Mutlu Arat21
Estimated H-index: 21
+ 8 AuthorsFevzi Altuntas14
Estimated H-index: 14
Abstract Autologous hematopoietic cell transplantation (AHCT) is a routinely used procedure in the treatment of adult patients presenting with multiple myeloma (MM), Hodgkin lymphoma (HL) and various subtypes of non-Hodgkin lymphoma (NHL) in upfront and relapsed/refractory settings. Successful hematopoietic progenitor cell mobilization (HPCM) and collection are the rate limiting first steps for application of AHCT. In 2015, almost 1700 AHCT procedures have been performed for MM, HL and NHL in Tu...
Published on Dec 1, 2017in Transfusion and Apheresis Science 1.41
Mehmet Hilmi Dogu3
Estimated H-index: 3
,
Seckin Cagirgan1
Estimated H-index: 1
(Medical Park)
+ 10 AuthorsSibel Hacioglu8
Estimated H-index: 8
(Pamukkale University)
Abstract As known, the world population is aging and as the life span increases the number of advanced-age lymphomas also shows an upward trend. Autologous hematopoietic stem cell transplantation (HSCT) is the standard treatment modality in chemotherapy-sensitive relapsed or refractory aggressive lymphomas. Increased morbidity and mortality related to both the transplant itself and comorbid diseases can be observed in elderly lymphoma patients. Patients who are 65 years or older and underwent au...
Published on Dec 1, 2017in Transfusion and Apheresis Science 1.41
Emre Tekgündüz8
Estimated H-index: 8
,
Fatih Demirkan11
Estimated H-index: 11
(Dokuz Eylül University)
+ 25 AuthorsSeckin Cagirgan9
Estimated H-index: 9
Abstract Autologous hematopoietic cell transplantation (AHCT) is an established treatment option for adult patients presenting with multiple myeloma (MM), Hodgkin lymphoma (HL) and various subtypes of non-Hodgkin lymphoma (NHL) in upfront and/or relapsed/refractory disease settings. Although there are recently published consensus guidelines addressing critical issues regarding autologous hematopoietic progenitor cell mobilization (HPCM), mobilization strategies of transplant centers show high va...
123456789